l-Amino acid ligase catalyzes the formation of an α-peptide bond from unprotected l-amino acids in an ATP-dependent manner, and this enzyme is very useful in efficient peptide production. We performed enzyme purification to obtain a novel l-amino acid ligase from Bacillus subtilis NBRC3134, a microorganism producing peptide-antibiotic rhizocticin. Rhizocticins are dipeptide or tripeptide antibiotics and commonly possess l-arginyl-l-2-amino-5-phosphono-3-cis-pentenoic acid. The purification was carried out by detecting l-arginine hydroxamate synthesis activity, and a target enzyme was finally purified 1,280-fold with 0.8% yield. The corresponding gene was then cloned and designated rizA. rizA was 1,242 bp and coded for 413 amino acid residues. Recombinant RizA was prepared, and it was found that the recombinant RizA synthesized dipeptides whose N-terminus was l-arginine in an ATP-dependent manner. RizA had strict substrate specificity toward l-arginine as the N-terminal substrate; on the other hand, the substrate specificity at the C-terminus was relaxed.
l-氨基酸连接酶以依赖 ATP 的方式催化未受保护的 l-氨基酸形成 α-肽键,这种酶对高效生产多肽非常有用。我们进行了酶纯化,从生产多肽抗生素根肿灵的微生物枯草芽孢杆菌(Bacillus subtilis NBRC3134)中获得了一种新型 l-氨基酸连接酶。根瘤菌素是一种二肽或三肽抗生素,通常含有 l-精氨酰-l-2-氨基-5-磷酰基-3-顺式戊烯酸。通过检测精氨酰羟氨酸盐合成活性进行纯化,最终纯化出目标酶 1280 倍,产率为 0.8%。然后克隆了相应的基因,并将其命名为 rizA,rizA 的长度为 1 242 bp,编码 413 个氨基酸残基。研究人员制备了重组 RizA,发现重组 RizA 能以 ATP 依赖性方式合成 N 端为 l-精氨酸的二肽。RizA对N端底物精氨酸具有严格的底物特异性,而对C端的底物特异性则比较宽松。
Human tissue plasminogen activator, pharmaceutical compositions containing it, processes for making it, and DNA and transformed cell intermediates therefor
申请人:GENENTECH, INC.
公开号:EP0093619A1
公开(公告)日:1983-11-09
Human tissue plasminogen activator (t-PA) is produced In useful quantities using recombinant techniques. This invention thus enables production of t-PA free of contaminants associated with it in its native cellular environment. Methods, expression vehicles and various host cells useful in its production are also disclosed.
DIPEPTIDE-CONTAINING COMPOSITION FOR ORAL ADMINISTRATION
申请人:KYOWA HAKKO KOGYO CO., LTD.
公开号:EP1941896A1
公开(公告)日:2008-07-09
The present invention provides a composition for oral administration, which comprises at least one kind of dipeptide represented by the formula:
X-Y
(wherein X represents alanyl, glycyl, arginyl, seryl, α-aspartyl or α-glutamyl, and Y represents valine, leucine or isoleucine), with an object of providing a composition for oral administration which is excellent in nutrition, pharmacological effect and gustation and comprises at least one kind selected from valine, leucine and isoleucine, or providing a composition for oral administration which is excellent in processing characteristics such as solubility and tableting property and comprises at least one kind selected from valine, leucine and isoleucine.
本发明提供了一种口服组合物,它包含至少一种由式表示的二肽:
X-Y
(其中 X 代表丙氨酰、甘氨酰、精氨酰、丝氨酰、α-天冬氨酰或α-谷氨酰,Y 代表缬氨酸、亮氨酸或异亮氨酸),其目的是提供一种营养、药效和口感俱佳的口服组合物,该组合物至少包含一种选自缬氨酸、亮氨酸和异亮氨酸的二肽、或提供一种口服组合物,该组合物在加工特性(如溶解性和压片性能)方面非常出色,并包含至少一种选自缬氨酸、亮氨酸和异亮氨酸的成分。
TRYPTOPHAN AS A BIOMARKERS FOR KIDNEY FUNCTION AND METHODS USING THE SAME
申请人:Metabolon, Inc.
公开号:EP3410115A1
公开(公告)日:2018-12-05
Biomarkers of kidney function and methods for using said biomarkers for assessing kidney function, monitoring kidney function, diagnosing acute kidney injury, and diagnosing chronic kidney disease are provided. Also provided are suites of small molecule entities as biomarkers for chronic kidney disease.